Changes in Hong Kong stocks | Ruibo Bio-B (06938) rose more than 6% to acquire remaining shares in Ribocure Pharmaceuticals AB

The Zhitong Finance App learned that Ruibo Biotech B (06938) rose by more than 6%. As of press release, it had risen 6.52% to HK$53.9, with a turnover of HK$2,502,900.

According to the news, Ruibo Biotech announced that on October 16, 2026, the company signed a share exchange agreement with minority shareholders. According to this, subject to and in accordance with the terms and conditions of the share exchange agreement, the company has already conditionally agreed to the acquisition, and the minority shareholders have separately and conditionally agreed to sell the target shares (together accounting for 49.71% of the total number of issued shares of the target company), so that the company will hold all of the target company's interests.

The target company Ribocure Pharmaceuticals AB is a clinical-stage biotechnology company established in February 2022 under Swedish law. As the company's international R&D center, the target company is mainly engaged in global clinical development and translational research of oligonucleotide therapies, with a special focus on siRNA drugs for cardiovascular, metabolic, liver, kidney and neurodegenerative diseases. The target company currently has five drug discovery and pre-clinical projects, two of which have advanced to the near clinical declaration stage and two major external licensing cooperation projects.